Moderna updated COVID-19 vaccine effective against Eris, Fornax variants
Carl Court
Moderna (NASDAQ:MRNA) said Thursday that preliminary clinical data has confirmed its updated COVID-19 vaccine generates a robust immune response against the EG.5 and FL 1.5.1 variants.
The company noted that EG.5, or Eris, is now the dominant variant strain in the US, while the FL 1.5.1, or Fornax, variant has been spreading quickly in certain areas of the country. 
Moderna said previously it had only presented data confirming the updated vaccine triggered a robust response against key XBB strains of the virus that causes COVID-19. 
The company has submitted applications to US, EU and other global regulators to have the updated vaccine authorized for use for the fall vaccination season. It added that pending authorization, it expects to have sufficient global supply. 

More on Moderna

Moderna Falling As Vaccine Hesitancy Rises

Moderna, Inc. (MRNA) Q2 2023 Earnings Call Transcript
Moderna, Inc. 2023 Q2 - Results - Earnings Call Presentation
BioNTech And Moderna: Fallen Angels Of The COVID Era Are Buys Ahead Of Earnings
Moderna hires former former UK government health official
Inside COVID-19 vaccine makers: Hope vs hype
WHO names newly dominant EG.5 strain as COVID 'variant of interest'
Why did Moderna stock go down today? Bearish views pile up
Seeking Alphaâs Quant Rating on Moderna
Earnings data for Moderna